Skip to content
B-LCL-CDG5
Tissue
外周血
Disease
EBV 轉化之 B 淋巴母細胞樣細胞系(B-LCL);PMM2-CDG(先天性糖基化障礙,源自患者)
Metastatic site
不適用(EBV 轉化性 B 細胞淋巴細胞樣細胞瘤;非轉移性)

Documents

B-LCL-CDG5

Cell line · Product number 302016

B-LCL-CDG5 is an EBV-transformed B lymphocyte cell line derived from a patient with PMM2-CDG, a congenital disorder of glycosylation (CDG) caused by mutat...

US$800.00excl. tax and shipping
Made to order
1

01General information

Description

B-LCL-CDG5 是一種源自 PMM2-CDG 患者的 EBV 轉化 B 淋巴細胞系,PMM2-CDG 是一種由 *PMM2* 基因突變所引起的先天性糖基化障礙(CDG)。 此疾病會妨礙糖鏈結構的正常合成及其與糖蛋白和糖脂的結合,進而影響多個器官系統。 磷酸甘露糖轉化酶 2(PMM2)的缺乏會干擾甘露糖-6-磷酸轉化為甘露糖-1-磷酸的過程——這是糖基化中的關鍵步驟——進而導致細胞功能缺陷及全身性併發症。

作為一種經 EBV 永生化的 B 細胞系,B-LCL-CDG5 是研究 *PMM2* 突變之生化與分子效應的關鍵模型。此細胞系使研究人員能夠探究糖基化缺陷、PMM2 酶活性,以及糖基化受損所導致的細胞後果。 此外,它還提供了一個測試潛在治療方法的平台,例如藥理學伴侶蛋白、酶活化療法或底物補充策略。B-LCL-CDG5 結合其他源自 CDG 患者的細胞系,有助於深化我們對 PMM2-CDG 的理解,並推動靶向治療方案的開發。

Tissue
外周血
Disease
EBV 轉化之 B 淋巴母細胞樣細胞系(B-LCL);PMM2-CDG(先天性糖基化障礙,源自患者)
Metastatic site
不適用(EBV 轉化性 B 細胞淋巴細胞樣細胞瘤;非轉移性)
Applications
免疫細胞中 CDG 效應的基因分型、功能檢測(例如 B 細胞表面抗原)、細胞毒性藥物檢測。突變分析、凋亡機制分析、HLA 分型,以及特定細胞糖蛋白糖基化缺陷對各種功能之影響。

02Classification

Organism
Human
Sex
Female
Growth properties
Suspension
GMO status
GMO-S2
GMO status details
GMO-S2: This B-LCL contains a stably maintained EBV episome encoding viral latent-phase genes (EBNA-1/-2/-3, LMP-1/-2). EBV is a risk group 2 pathogen; BSL-2 containment required. This classification applies within Germany; regulations may differ elsewhere.
Biosafety level
2

03Characteristics

Morphology
圓形細胞
Cell type
B 淋巴細胞

04Identifiers

Citation
B-LCL-CDG5(Cytion 型號 302016)
NCBI TaxID
9606
Cellosaurus
Not assigned

05Expression and susceptibility

Viruses
轉化體:EBV

06Handling and culture

Culture medium
RPMI 1640,含 2.0 mM 穩定谷氨醯胺,含 2.0 g/L NaHCO₃(Cytion 產品編號 820700a)
Incubation atmosphere

37°C,5% CO₂,加濕環境。

Supplements
在培養基中加入 10% 經熱滅活的胎牛血清
Subculturing
透過定期添加或更換培養基來維持培養。起始培養時,細胞密度應為 2 × 10⁵ 個細胞/毫升,並將細胞濃度維持在 1 × 10⁵ 至 5 × 10⁵ 個細胞/毫升的範圍內,以達到最佳生長效果。
Fluid renewal
當那中等色調轉為黃色時
Post-thaw recovery
中
Thawing and culturing
  1. Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.

  2. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.

  3. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.

  4. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.

  5. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.

  6. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium.

  7. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks; for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth.

  8. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes.

07Quality control and cryopreservation

Sterility

透過基於 PCR 的檢測及基於發光原理的支原體檢測方法,排除支原體污染的可能性。

為確保無細菌、真菌或酵母菌污染,每日均會對細胞培養物進行目視檢查。

Freeze medium
作為冷凍保存培養基,我們使用完全生長培養基(含 FBS)+ 10% DMSO 以確保解凍後的存活率,或使用 CM-1 (Cytion 型號 800100),該培養基含有經優化的滲透保護劑和代謝穩定劑,可提升細胞恢復率並減輕冷凍誘導的壓力。
Storage conditions

若需長期保存,請將試管置於溫度約為 −150 至 −196 °C 的氣相液氮中。僅在轉移至液氮之前,可將試管暫時存放於 −80 °C 環境中,作為短期過渡步驟。

Shipping conditions

冷凍保存的細胞系會以乾冰冷藏,並裝於經驗證的隔熱包裝中,包裝內含有足夠的冷媒,以確保在運輸過程中溫度維持在約 −78 °C。收到貨物後,請立即檢查容器,並盡快將試管轉移至適當的儲存場所。

08Donor

Ethnicity
高加索人